# US 2018/0022818 A1 · Methods and products for preventing and/or treating metastatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022818 A1
- Document ID: US20180022818A1
- Status: Published application
- Kind: A1
- Application number: 15/656,611
- Filed: 2017-07-21
- Published: 2018-01-25
- Earliest claimed: 2012-09-06
- Assignees: Adelaide Research & Innovation Pty Ltd
- Applicants: Adelaide Research & Innovation Pty Ltd; Peter MacCallum Cancer Institute
- Inventors: Shaun Reuss McColl; Ian Comerford; Yuka Harata-Lee; Mark Smyth
- Web page: https://patentgrep.com/patent/US20180022818A1

## CPC

- C07K 16/3053: {Skin, nerves, brain}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/30: from tumour cells
- C12N 15/1138: {against receptors or cell surface proteins}
- G01N 33/5011: {for testing antineoplastic activity}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C12N 2310/14: interfering nucleic acids [NA]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a catalyst precursor and a catalyst suitable for preparing multi-wall carbon nanotubes. The resulting multi-wall carbon nanotubes have a narrow distribution as to the number of walls forming the tubes and a narrow distribution in the range of diameters for the tubes. Additionally, the present invention provides methods for producing multi-wall carbon nanotubes having narrow distributions in the number of walls and diameters. Further, the present invention provides a composition of spent catalyst carrying multi-wall nanotubes having narrow distribution ranges of walls and diameters.

## Claims

### Claim 1

A method of inducing an immune response to a cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.

### Claim 2 (depends on 27)

The method according to claim 27, wherein the cancer is a metastatic cancer.

### Claim 3 (depends on 27)

The method according to claim 27, wherein the inhibitor comprises one or more of a small interfering RNA, a microRNA, an antisense RNA, a ligand for a chemokine receptor CCX-CKR, and an antibody and/or an antigen binding part thereof.

### Claim 4 (depends on 27)

The method according to claim 27, wherein administering the inhibitor to the subject induces anti-tumour CD4+ and/or CD8+ cells in the subject.

### Claim 5

An antibody to a chemokine receptor CCX-CKR and/or an antigen binding part thereof, wherein the antibody and/or the antigen binding part thereof inhibits metastasis of a cancer in a subject.

### Claim 6 (depends on 29)

The antibody and/or antigen binding part thereof according to claim 29, wherein the cancer is a melanoma, a breast cancer, a prostate cancer, an ovarian cancer, or a colorectal cancer.

### Claim 7 (depends on 29)

The antibody and/or antigen binding part thereof according to claim 29, wherein the antibody and/or the antigen binding part thereof binds to one or more amino acids and/or an epitope located in one or more of the following regions of the human chemokine receptor CCX-CKR: amino acids 1 to 42, amino acids 109 to 113, amino acids 176 to 201, and amino acids 262 to 289; or an equivalent region of the receptor in another species.

### Claim 8

A cell expressing an antibody and/or antigen binding part thereof according to claim

### Claim 9 (depends on 29)

A method of preventing and/or treating metastatic cancer in a subject, the method comprising administering to the subject an effective amount of an antibody and/or an antigen binding part thereof according to claim 29.

### Claim 10 (depends on 33)

The antibody and/or antigen binding part thereof according to claim 33, wherein the antibody and/or the antigen binding part thereof binds to one or more amino acids and/or an epitope located in amino acids 1 to 42 of the human chemokine receptor CCX-CKR.

### Claim 11 (depends on 68)

The antibody and/or antigen binding part thereof according to claim 68, wherein the antibody and/or the antigen binding part thereof binds to an one or more amino acids and/or an epitope in one or more of polypeptide sequences: SEQ ID NOs. 5 to 24.

### Claim 12 (depends on 29)

The antibody and/or antigen binding part thereof according to claim 29, wherein administering the antibody and/or antigen binding part thereof to the subject induces anti-tumour CD4+ and/or CD8+ cells in the subject.